$387.700
-2.210 (-0.57%)Al cierre
Noticias de BIO
Eventos de BIO
Bio-Rad Implements Restructuring Plan Estimated Costs Up to $90 Million
According to a regulatory filing, on July 31, 2026, Bio-Rad Laboratories initiated a strategy-driven restructuring plan as part of our ongoing program to improve operating performance and strengthen the Company's competitive position. "The restructuring plan impacts our operations and functions throughout the world and includes the elimination of certain positions, the consolidation of certain functions, and the closure of various facilities," the company said. "We estimate that we will incur total pre-tax charges of approximately $80 to $90 million, which we anticipate will consist primarily of one-time termination benefits, including cash severance payments, healthcare benefits, and related transition assistance. The estimates for headcount reduction, timing and charges in certain areas of the international business are subject to completion of applicable local employee consultative processes. The restructuring plan is expected to be substantially completed by the end of fiscal year 2027."
Bio-Rad Reports Q2 Revenue of $651M, Beating Expectations
Reports Q2 revenue $651M, consenesus $623.99M. Norman Schwartz, Bio-Rad's Chairman and Chief Executive Officer, stated: "Second-quarter reported revenue was flat year-over-year, with growth in Clinical Diagnostics offset by continued softness in Life Science. Despite Life Science headwinds, our digital PCR instrument revenue grew more than 20%. EMEA returned to growth, aided by Middle East channel restocking amid continued volatility in the region. During the quarter, we generated $99 million in operating cash flow, and repurchased approximately $32 million of shares. We are reaffirming our full-year outlook, and remain focused on the discipline we believe will drive growth, durable margin expansion, and long-term shareholder value creation."
Company Expects 2026 Non-GAAP Revenue to Decline Approximately 3%
For the full-year 2026, the Company continues to expect non-GAAP, currency-neutral revenue to be in the range of a decline of approximately 3.0 percent to growth of approximately 0.5 percent, and an estimated non-GAAP operating margin of approximately 10.0 to 12.0 percent.
Sartorius Shares Drop After Competitor Earnings Report
Sartorius (SSSGY) shares are trading lower in Europe after earnings from competitor Danaher (DHR), including bioprocessing unit results that missed expectations. Bio-Rad Laboratories (BIO), which owns a $5B strategic stake in the German biopharma equipment supplier, is down about 1% in early trading in New York.
U.S. Stocks Mostly Lower at Noon as Oil Prices Climb
Stocks were mostly lower near noon following a record-setting week as investors continue to watch climbing oil prices while awaiting more developments out of the Middle East. The 30-year Treasury yield climbed above 5.15%, its highest level since before the 2008 financial crisis, while the 10-year Treasury yield rose toward 4.65%. Investors are increasingly worried that inflation is becoming entrenched due to energy prices, persistent fiscal deficits and resilient economic demand. Markets are now pricing in a meaningful possibility that the Federal Reserve could raise rates again later this year instead of cutting them.Semiconductor and mega-cap tech stocks remain the market's leadership group, but investors are becoming more sensitive to valuations as borrowing costs rise. Analysts are increasingly debating whether AI enthusiasm has become excessive, particularly given the massive capital spending required to sustain the boom.Get caught up quickly on the top news and calls moving stocks with these five Top Five lists.1. STOCK NEWS:Dominionand NextEra Energyin an all-stock transactionPublicisLiveRampfor $2.2BFordand EDF Group announced the signing of aRegeneronsaid its Phase 3 trial of fianlimabMacy'sand Delta Air Lineswere higher after Berkshire Hathaway2. WALL STREET CALLS:F5to Outperform from In Line at Evercore ISIZscalerto Buy at B. RileyCoreWeaveand Nebiuswith lowered Neutral ratings as a new analyst took over coverage at DA DavidsonApplied Materialsto Equal Weight at Morgan StanleySalesforcewith an Underperform at BofA amid structural reset3. AROUND THE WEB:Apple'srevamped Siri may launch in beta, and will have an option to auto-delete chats, Bloomberg reportsU.S. President Donald Trump said he "should have asked for more" of a stake in Intelon behalf of the U.S. government, Fortune saysFugazi Research issued a cautious note on MMTECActivist investor Elliot Investment Management has built a big stake in Bio-Rade Laboratories, with plans to push the company to boost its underperforming stock price, WSJ saysVinFast'splanned sale of two Vietnamese factories will allow the company to shed $6.9B in debt and obligations to help assist its path to profitability, Bloomberg says4. MOVERS:Hive Digitalhigher after announcing its subsidiary is planning to build a newin the Greater Toronto Area with approximately 320 megawatts of utility capacityCourseraincreases after announcing a $500MServiceNowgains after BofAof the stock with a Buy ratingDesign Therapeuticslower afterfrom its RESTORE-FA trialPoet Technologiesfalls after closing a5. EARNINGS/GUIDANCE:Bradyand raised its guidance for FY26iQiyi, with EPS and revenue lower year-over-yearGossamer Bio, with CEO Faheem Hasnain commenting, "We are executing across multiple fronts at Gossamer"RedCloudand reaffirmed guidance for FY26Baidu, with EPS and revenue lower year-over-yearINDEXES:Near midday, the Dow was up 0.02%, or 12.01, to 49,538.18, the Nasdaq was down 0.60%, or 157.04, to 26,068.11, and the S&P 500 was down 0.25%, or 18.29, to 7,390.21.
Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.